Wednesday, February 10, 2010, 6:09pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Isis Pharmaceuticals, Inc. (ISIS)

At 5:00AM SGT: 11.04 USD   0.00 (0.00%)  
 MORE ON ISIS 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Isis Pharmaceuticals, Inc. (NasdaqNM:ISIS) Delayed quote dataEdit
Last Trade:11.04 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:11.04
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:20.40
Day's Range:N/A - N/A
52wk Range:9.77 - 18.81
Volume:0
Avg Vol (3m):1,431,610
Market Cap:1.09B
P/E (ttm):6.83
EPS (ttm):1.62
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add ISIS to Portfolio   Download Data

 HEADLINES 
•10 Biotech Stocks on Clinical Trials Watch
at TheStreet.com (Thu, Feb 4)
•Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
Business Wire (Mon, Jan 25)
•Isis Expands Pipeline
Zacks.com (Mon, Jan 18)
•Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
Business Wire (Fri, Jan 15)
•These 5 Underdogs Are No Dogs
at Motley Fool (Thu, Jan 14)
•Dream Stocks for Contrarian Investors
at Motley Fool (Wed, Jan 13)
•Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Business Wire (Mon, Jan 11)
•Isis Pharmaceuticals Adds New Cardiovascular Drug to Development Pipeline
PR Newswire (Mon, Jan 11)
•3 Stocks in a Tailspin
at Motley Fool (Fri, Jan 8)
•Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
PR Newswire (Wed, Jan 6)
•Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001
PR Newswire (Tue, Jan 5)
More Headlines for ISIS...
 ANALYST 
EPS Est (next year) (Dec-09) :1.51
EPS Est (in 2 years) (Dec-10) :-0.33
Avg Rec (current)*:1.9
PEG Ratio:0.26
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Isis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices